← Back to blog

What Does "Enriched Flour" Mean? Why Folic Acid Is in Your Bread

Open a loaf of supermarket bread. Read the ingredient label.

The first words are almost always enriched wheat flour. Then, in smaller print: niacin, reduced iron, thiamin mononitrate, riboflavin, folic acid.

Most people have read those words a thousand times and never thought to ask what they mean.

Folic acid is in there because of a 1996 FDA rule. Not a law passed by Congress — Congress never voted on a "Folic Acid Bread Act." A rule is a federal regulation. Congress gave the FDA authority to set food standards a long time ago; in March 1996 the FDA used that authority to amend its standards of identity for enriched cereal-grain products. The amendment requires that anything sold as enriched flour, bread, pasta, rice, or cornmeal contain 140 micrograms of folic acid per 100 grams of flour — about 0.7 milligrams per pound. The rule took effect January 1, 1998.

The subtle point worth holding onto: no miller is required to make flour enriched. They are free to sell unenriched white flour, whole-wheat flour, gluten-free flour, specialty flour, anything they want. But if they put the word enriched on the bag, the legal definition of that word now includes folic acid. Same goes for bakers, pasta makers, and cereal companies who buy that flour and put the word enriched on their box.

So the law isn't every loaf must contain folic acid. The law is the word "enriched" now means something specific, and that specific thing includes folic acid. Most Americans encounter folic acid in many ordinary grain-based foods not because it was made universally mandatory, but because enriched flour has been the commercial default since the 1940s — and the FDA quietly added folic acid to the definition of enriched in 1998.

Most people have never thought to ask why.

That's the question this post is about. Not whether the policy was wise, exactly. Not whether anyone did anything wrong. But how the bread on your shelf came to contain a synthetic vitamin that wasn't in it 28 years ago, what the story is behind it, and what the story doesn't tell you about a gene that more than half of you probably carry.

What "enriched" actually means

When wheat is milled into white flour, the milling process strips out two specific parts of the wheat kernel: the bran (the fiber-rich outer coating) and the germ (the inner nutrient-rich embryo). What's left is the endosperm — the starchy white middle, which is what gets ground into flour.

The bran and germ are where most of the wheat's nutrients live: B vitamins, magnesium, iron, fiber, antioxidants. Strip them out, and what's left is mostly starch and protein.

The whole point of enrichment is to put some of those nutrients back. After the flour is milled but before it's bagged or shipped, the miller adds a powder containing a specific set of vitamins and minerals — currently iron, thiamin (B1), riboflavin (B2), niacin (B3), and folic acid (B9). The dosing is set by FDA regulation: 140 micrograms of folic acid per 100 grams of enriched flour, plus the other required vitamins at their specified levels.

The miller does this at the end of the milling line, in the last few minutes before the flour leaves the plant. It costs a few cents per hundred pounds. From a commercial standpoint, it's almost free.

By the time a bakery, a school cafeteria, or a supermarket private-label brand receives the flour, the folic acid is already in it, mixed evenly through every bag. The bakery doesn't add it. The supermarket doesn't add it. The miller did. The decision was made decades before that particular bag of flour ever existed.

How we got to enriched

The story doesn't start in 1996. It starts in the 1940s.

During World War II, American nutrition policy turned toward flour because flour was everywhere. White flour had become the default, but industrial milling stripped out the bran and germ — taking much of the grain's natural B vitamins and minerals with it. Army physicals were turning up widespread deficiencies — beriberi, pellagra, and the subclinical fatigue that comes from inadequate thiamin, riboflavin, and niacin. Recruits going to war underfed in important ways.

The first enrichment standards were built around that problem. Thiamin, riboflavin, niacin, and iron were added back to refined flour and bread to repair what milling had stripped away. Wartime food orders pushed enrichment broadly. Later federal standards made the meaning of the word enriched legally specific.

That distinction matters.

The government did not make every loaf of bread a vitamin pill. It created a standard: if flour or bread was sold as enriched, it had to contain the nutrients required by that standard. Bakers and millers chose to use enriched flour because that's what the market wanted. But the meaning of the word, once written, was no longer up to the miller.

Over time, enriched white flour became the commercial default. Whole grain became the niche. And the word enriched became so familiar that almost nobody stopped to ask what had been removed, what had been added back, or why.

This is the structural fact most people don't realize: the enrichment system in your bread has been running for over eighty years. Iron, thiamin, riboflavin, and niacin have been added to American refined flour since your grandparents were eating sandwiches at lunch counters. The pipes were laid down in the 1940s, and they've been running ever since.

Folic acid is the newcomer. It was added in 1996, took effect in 1998, and unlike the original four, joined an existing distribution machinery built for a different purpose. The bread didn't change. The flour did. And the folic acid was poured in through pipes that had been laid down half a century before for an entirely different reason.

To understand why folic acid joined the list, you have to understand what it was being asked to do.

Why folic acid

The question that drove the 1996 rule was a public health question about neural tube defects — spina bifida and anencephaly.

Spina bifida is when the spine fails to close completely during early fetal development; the baby is born paralyzed below the lesion, with bowel and bladder dysfunction and a lifetime of surgeries. Anencephaly is when the brain and skull fail to develop; the baby is either stillborn or dies within days. Together, these defects affected roughly 1 in 1,000 American pregnancies in the early 1990s — about 4,000 cases per year.

The neural tube — the structure that becomes the spine and brain — closes between days 21 and 28 of gestation. Before most women even know they are pregnant.

By 1991, researchers had assembled a strong scientific case that folic acid supplementation around the time of conception substantially reduced NTD risk. The biggest single piece of evidence was a randomized controlled trial run by the UK Medical Research Council, published in The Lancet that year, which showed a 72% reduction in NTD recurrence in women supplementing with 4 milligrams per day of synthetic folic acid. A 1992 trial led by András Czeizel and István Dudás in Hungary, published in the New England Journal of Medicine, confirmed the effect for first-occurrence NTDs.

In 1992, the US Public Health Service recommended that all women of childbearing age consume 400 micrograms of folic acid daily. In 1993, the FDA proposed a fortification rule. In March 1996, the Final Rule was published. In January 1998, it went into effect.

Two questions are worth pulling apart here, because most public discussion of this policy collapses them.

Did the FDA have evidence to act on? Yes. The MRC trial alone was strong evidence — randomized, controlled, published in a top journal, replicated by the Hungarian trial the next year. The supplementation–prevention link was real. The science was solid.

Was the FDA's leap from "supplements prevent recurrence in women planning pregnancy" to "synthetic folic acid in every loaf of bread in America" a different kind of decision? Yes. That's the leap. The trials had tested high-dose supplementation in a specific high-risk group. The policy translated that into a low-dose, lifelong, population-wide exposure delivered through the food supply, with no controlled trial of the policy itself.

The policy logic was: half of American pregnancies are unplanned, the neural tube closes before most women know they're pregnant, so a supplementation recommendation can't reach everyone — but if folic acid is in the food supply, everyone gets some exposure passively. That's a coherent argument inside a public-health model. It's not nonsense.

But it is a different argument than the one the trials were testing. The trials answered: does giving high doses of folic acid to women trying to prevent recurrence reduce NTDs? The policy answered: will giving low doses to the entire population, every day, for the rest of their lives, reduce population NTD rates? Those are two different questions. The first has good evidence. The second has had the policy in place for 28 years and the evidence is the policy itself.

About 1,300 NTD cases are prevented in the US each year under fortification, by CDC estimates. That is real. NTD birth prevalence went from about 10.8 per 10,000 to about 6.9 per 10,000 in the years after fortification began — roughly a 27% reduction. Some of that decline is fortification. Some of it is voluntary prenatal supplementation, better prenatal care, and the spread of prenatal ultrasound screening combined with elective termination of diagnosed NTDs. The actual fortification-specific effect is contested in the literature — several analyses put it below the headline 27% once the other factors are accounted for.

What is not contested: fortification did not solve NTDs. It reduced them. About 2,500 NTD pregnancies a year still occur in fortified America, despite the policy.

Those 2,500 — and the women who carry those pregnancies — are where the rest of this post lives.

The doctor who saw it first

There is a name behind all of this that almost nobody outside the field has heard: Richard Smithells.

Smithells was a British paediatrician working in Leeds in the 1960s. He was not a celebrity researcher. He was a clinician who saw, week after week, mothers giving birth to babies with NTDs, and could not tell them why. The condition seemed random. Some families had it; most didn't. Patterns appeared and dissolved.

Working with a colleague named Elizabeth Hibbard, Smithells started running tests on the mothers of NTD babies to look for clues in their biochemistry. The test he used was called the FIGLU excretion test.

FIGLU stands for formiminoglutamic acid. It's a compound your body produces when it breaks down the amino acid histidine. The breakdown step requires folate as a cofactor. If your folate metabolism is running properly, FIGLU gets processed and disappears. If your folate metabolism is not running properly, FIGLU spills into your urine where a clinician can measure it.

Smithells found that mothers of NTD babies had abnormal FIGLU.

Their folate metabolism was not running right.

What he did next was the move that defined his career. He hypothesized that supplementing folate before and during early pregnancy might prevent NTDs in this population. He used a multivitamin called Pregnavite Forte F, which contained 360 micrograms (0.36 mg) of folic acid plus seven other vitamins. He gave it to women who had already had one NTD pregnancy and were trying again. He compared their outcomes to women who didn't take the supplement.

His first paper, published in The Lancet in 1980, reported a substantial reduction in recurrences. He confirmed it in 1981. He confirmed it again in 1983. He confirmed it again in 1989 with the final Yorkshire report.

The medical establishment wasn't ready. Smithells' trials weren't randomized — women self-selected into supplementation, and the journals worried about confounding. A randomized controlled trial was demanded. That trial — the MRC Vitamin Study of 1991 — used a dose of 4 milligrams of folic acid per day, more than ten times what Smithells had used in Pregnavite Forte F. The result was the 72% recurrence reduction that became the foundation of every fortification policy in the world that followed.

That 4-milligram dose was for women at high recurrence risk. Fortification delivers far less. Most Americans get 100 to 200 micrograms of folic acid per day from fortified grains — less than Smithells' 360 mcg, and dramatically less than the MRC's 4 mg. The data underlying fortification came from supplementation doses different from what the food supply actually delivers. Nobody has ever run a controlled trial of fortification at fortification doses. The assumption is that the trial results scale down.

But here's where it gets actually interesting

What Smithells was measuring with his FIGLU test was something wrong with how these mothers processed folate. Not necessarily that they were eating too little. Not necessarily that their blood folate was low. In fact — and this is the part that almost never makes it into the public-health version of the story — many of the mothers in his studies had blood folate levels within the normal range.

That isn't a deficiency.

That's evidence that folate-dependent metabolism wasn't running cleanly.

That isn't proof of MTHFR. FIGLU is not an MTHFR test. It's a broader sign that the one-carbon cycle — the chemistry that makes methyl groups available to your DNA, your neurotransmitters, and the rest of your machinery — may be under strain. There are several genes and several cofactors that can put it under strain.

But once MTHFR was identified, the old observations became harder to ignore.

In 1994, researchers identified and cloned the human gene for an enzyme called methylenetetrahydrofolate reductase — MTHFR. The enzyme has a narrow and specific job: it converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF) — the methylated folate form used in homocysteine recycling and in the methylation reactions downstream. Folic acid, the synthetic form added to flour, doesn't enter the cycle at the MTHFR step. It has to be reduced first by a different enzyme called DHFR before it ever reaches MTHFR. The DHFR step is slow and saturable in humans. MTHFR is the bottleneck downstream.

In 1995, a group led by Frosst identified a common variant of MTHFR: C677T. People homozygous for this variant — both copies of the gene carry the variation — have MTHFR enzyme activity reduced to about 30% of normal. Heterozygous carriers run at about 65%. Roughly 50 to 60% of the population carries at least one variant copy.

That same year, a Dutch group led by van der Put published the first study linking maternal MTHFR C677T variants to neural tube defect risk. The connection held up across subsequent research. By 2012, a meta-analysis pooling 25 case-control studies — nearly 6,000 mothers in total — concluded that homozygous TT mothers had roughly double the NTD risk of mothers with the standard CC genotype, and that having even one variant copy raised risk by about 30%.

Now go back to Smithells' 1960s mothers. The ones with normal blood folate and abnormal FIGLU. The ones whose folate metabolism wasn't running right but who weren't deficient by the standard measure.

We can't run the test on a 1965 cohort. The samples don't exist. So the careful question isn't did Smithells prove MTHFR before MTHFR had a name? He didn't. The careful question is:

That question is fair. Here's what we know now, in retrospect:

• MTHFR variants are present in roughly half the population
• Maternal MTHFR variants roughly double NTD risk in the offspring
• Carriers don't necessarily have low blood folate — they have impaired folate processing
• FIGLU is consistent with — though not specific to — exactly that kind of impairment
• High-dose folic acid can overcome a slow enzyme by piling substrate in front of it

What Smithells appears to have stumbled into, three decades before the gene was named, was a population of women whose folate metabolism was genetically impaired. He measured the impairment with a urine test. He brute-forced past it with a multivitamin. He prevented a meaningful number of babies' worth of disability and death.

He died on June 13, 2002 — seven years after the gene was identified.

And as far as the published record can tell, Smithells never publicly went back and connected his FIGLU observations to MTHFR. No retrospective essay. No interview for the record. No comment in a later paper. He saw the gene get cloned. He saw the variant identified. He saw the link to NTDs published. And the connection — which now seems almost inevitable — wasn't one he chose to draw publicly.

That silence is notable. It is not proof. But it is notable.

And there's a footnote here worth saying out loud, because skipping it would be hiding the mainstream view. The current CDC position is that people who carry common MTHFR variants can still process folic acid, and the CDC still recommends 400 micrograms of folic acid daily for women who could become pregnant. That's the position this post is talking around. You don't have to disagree with the CDC to ask whether form, dose, and genotype belong in the conversation. Asking is allowed.

The country that did the research waited until 2026

Here is the part that should sit with you.

The original observations were British. The Pregnavite Forte F trials were British. The 1991 MRC randomized trial that confirmed everything was British. Much of the early science of folate and NTD prevention came out of UK hospitals and UK research councils.

The American FDA, working with the British science, mandated fortification by 1996 and implemented it by 1998. Five years from definitive science to American law.

The British government did not mandate folic acid fortification of British flour on the same timeline. Or anywhere close to it.

The story isn't that British scientists rejected the policy. They didn't. The Scientific Advisory Committee on Nutrition — SACN — recommended mandatory folic acid fortification of flour in 2006. SACN reiterated that recommendation in 2009. SACN reaffirmed it again in 2017. The Food Standards Agency board supported it. Repeated UK scientific advice was that fortification should go ahead.

It still didn't go ahead. Successive governments declined to act on the advice. The hesitation was real — particularly around older adults and a phenomenon called B12 masking, where high folate intake normalizes the blood markers traditionally used to spot B12 deficiency, allowing the neurological damage of untreated B12 deficiency to develop underneath the radar. Modern lab testing has improved enough that B12 status can be measured directly, which reduces — but doesn't entirely erase — the broader question of what a daily population-wide folic-acid exposure looks like over a lifetime. Other questions came up about possible effects on cancer signaling at higher folate levels. But the scientific advice consistently was: do it, with controls. The government didn't.

The British mandate was finally announced in September 2021 — thirty years after the MRC trial. The legislation requires British millers to fortify non-wholemeal wheat flour with folic acid by the end of 2026.

As of the day this post is being written, British bread does not yet legally contain mandatory folic acid.

The interesting question isn't did Britain reject fortification? They didn't. The interesting question is:

1. Why did one country move in five years on the same science while another took more than thirty?

2. What was the British government worried about that the American FDA wasn't — and was that worry serving the public or stalling the public?

3. Was the American model too fast, or the British model too slow, or is this exactly what happens when a population-level intervention helps many people, carries unresolved questions for others, and leaves individual biology out of the decision?

I don't have answers to those. Nobody really does. But the questions are worth holding.

And now in 2026, you can read your own genome for $30

This is where history turns into something you can act on.

Until very recently, finding out whether you carry an MTHFR variant required either an expensive medical genetic test or a consumer service like 23andMe or AncestryDNA that reads about 700,000 specific positions in your genome looking for known common variants.

In October 2025, MyHeritage upgraded its consumer DNA test to whole genome sequencing — covering roughly 3 billion base pairs across the whole genome, instead of just 700,000 fixed positions. The kit is often around $20 during promotions. That is not a typo. The cheapest whole-genome sequencing in the world right now is being sold as a stocking stuffer. (The coverage depth is lower than a research lab would use for clinical-grade sequencing, but it still reads vastly more of your DNA than any chip-based test.)

What that means in practice: far more of your folate pathway is now readable than ever before at this price point. Not just the common MTHFR C677T and A1298C — also rarer MTHFR variants that older chip tests miss, plus MTRR, MTHFD1, RFC-1, BHMT, the rest of the one-carbon metabolism cluster. The genes that determine how well your body processes the folic acid in the bread you've been eating every day since 1998.

You can take that file to your doctor. You can ask:

• Do I carry MTHFR variants?
• Should I be getting my folate from food instead of relying on fortification?
• Should I be on methylfolate — the active form — instead of folic acid in my prenatal vitamin or my B-complex?
• Could the way I've been getting folate for the last 28 years have been working against me, not for me?

I am not going to tell you the answers. I don't know them. Your doctor probably doesn't know them either, and that is not their fault — this is a moving area of science and the clinical guidance has not caught up to what individuals can now find out about themselves at home.

But the questions are yours to ask.

Sapere Aude

A British paediatrician with a urine test noticed something in 1965.

A gene that helped explain it was named in 1995.

The food supply was changed in 1998, before genetic testing was anywhere near ordinary people's lives.

That isn't a villain story. It's a chronology.

The science of 1965 didn't have the tools to ask which mothers were carrying which variants. The science of 1991 didn't have the tools to ask which babies would benefit most. The food policy of 1996 was built with the only tools anyone had — population-scale evidence, population-scale rules, population-scale doses. It helped. It prevented real harm. The CDC's 400-microgram recommendation for women who could become pregnant is grounded in real evidence.

None of that is the question.

The question is what happens now that the tools have changed.

In 2026, you can read your own genome for the price of two fast-food meals. You can see your MTHFR variants, your MTRR variants, your folate-pathway machinery — the chemistry that determines how well the folic acid in your bread actually works for you. The questions Smithells could only ask about a population, you can ask about yourself. The questions the 1996 rule could only answer in aggregate, you can ask in particular.

That isn't an attack on public health.

It's the next question after public health.

When the measuring stick gets sharper, the assumptions built around the old stick deserve a second look. That's not a critique of the people who built the policy. That's what science is — new tools, new questions, new chance to ask whether the old answer still fits the person standing in front of you.

That's the lane foodZipper sits in. Not against the policy. After it. Asking the question the policy could never have been built to ask: given my variants, what questions should I be asking about the form, dose, and source of my folate?

Sapere aude.

Dare to know.

The policy did what it could with the tools it had. You have better tools now.

— B+

Published research cited in this post

foodZipper is free. Your file never leaves your device. Upload your DNA and see your MTHFR.